TAR projects

2024

Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments (STA)

Bimekizumab for treating moderate to severe hidradenitis suppurativa (STA)

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST)

Dapagliflozin for treating chronic kidney disease (STA)

Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) (STA)

Quizartinib for untreated FLT3-ITD-positive acute myeloid leukaemia (STA)

Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (FTA)

Ublituximab for treating relapsing multiple sclerosis (Cost comparison)

2023

Artificial Intelligence technologies for assessing skin lesions selected for referral on the urgent suspected cancer pathway to detect benign lesions and reduce secondary care specialist appointments (EVA)

Bimekizumab for treating axial spondyloarthritis (FTA)

Burosumab for treating X-linked hypophosphataemia in adults (STA)

Dupilumab for treating prurigo nodularis (STA)

Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia (STA)

Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma (STA)

Iptacopan for treating paroxysmal nocturnal haemoglobinuria (STA)

Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (STA)

Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (Rapid review)

SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (STA)

2022

Cipaglucosidase alfa with miglustat for treating Pompe disease (STA)

Dabrafenib with trametinib for treating advanced BRAF V600 mutation-positive non-small-cell lung cancer (STA)

Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (STA)

MRI fusion biopsy in people with suspected prostate cancer (DAR)

Pembrolizumab in combination with platinum-based chemotherapy for treating recurrent, persistent or metastatic cervical cancer (STA)

Personal KinetiGraph Movement Recording System for remote clinical management of Parkinson’s disease (DAR)

Somatrogon for treating growth disturbance in children and young people aged 3 and over (STA)

2021

Asciminib for chronic myeloid leukaemia after two or more tyrosine kinase inhibitors (STA)

Avatrombopag in combination for treating chronic immune thrombocytopenia (STA)

Cenobamate for focal onset seizures in epilepsy (STA)

Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (STA)

Daratumumab in combination for systemic, amyloid light-chain, untreated amyloidosis (STA)

Early CDT-Lung for assessing malignancy risk of indeterminate pulmonary nodules (DAR)

Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (FTA)

Tofacitinib for treating active ankylosing spondylitis (STA)

Tofacitinib for treating juvenile idiopathic arthritis (FTA)

Upadacitinib for treating active ankylosing spondylitis (STA)

2020

Baricitinib for treating moderate to severe atopic dermatitis (STA)

Galcanezumab for preventing migraine (STA)

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (STA)

KTE-X19 for treating relapsed or refractory mantle cell lymphoma (STA)

Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (STA)

OTL-200 for treating metachromatic leukodystrophy (STA)

Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) (STA)

2019

Entrectinib for treating NTRK fusion-positive solid tumours (STA)

Larotrectinib for treating NTRK fusion-positive advanced solid tumours (STA)

QAngio XA 3D/QFR imaging software for assessing coronary obstructions (DAR)

Secukinumab for treating non-radiographic axial spondyloarthritis (STA)

Selective internal radiation therapies for treating hepatocellular carcinoma (MTA)

Zynteglo for treating transfusion-dependent beta-thalassaemia (STA)

2018

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma, mediastinal B-cell lymphoma and follicular lymphoma (STA)

Certolizumab pegol for treating moderate to severe plaque psoriasis (STA)

Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (STA)

Letermovir prophylaxis for cytomegalovirus disease after allogeneic stem cell transplant (STA)

Liposomal cytarabine and daunorubicin for untreated acute myeloid leukaemia (STA)

Modelling approaches for histology independent cancer drugs (Methods project)

Point-of-care creatinine tests to assess kidney function before administering intravenous contrast for computed tomography (CT) imaging (DAR)

Tofacitinib for treating active psoriatic arthritis following disease modifying anti-rheumatic drugs (STA)

Tildrakizumab for treating moderate to severe plaque psoriasis (STA)

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (STA)

Tisagenlecleucel-T for treating relapsed or refractory diffuse large B-cell lymphoma (STA)

2017

Brodalumab for treating moderate to severe plaque psoriasis (STA)

Ceritinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (STA)

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST)

Etirinotecan pegol for treating breast cancer with brain metastases (STA)

Inotuzumab ozogamicin for treating relapsed or refractory acute lymphoblastic leukaemia (STA)

Management strategies for phantom limb pain (HTA Short Report)

Midostaurin for untreated acute myeloid leukaemia (STA)

Strimvelis for treating severe combined immunodeficiency caused by adenosine deaminase deficiency (HST)

Tocilizumab for treating active giant cell arteritis (STA)

Ustekinumab for previously treated moderate to severe active Crohn’s disease (STA)

2016

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (MTA)

Adjunctive colposcopy technologies for assessing suspected cervical abnormalities (Review of DG4) (DAR)

Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (STA)

Eliglustat for treating type 1 Gaucher disease (HST)

2015

Apremilast for the treatment of psoriatic arthritis (STA)

Apremilast for treating moderate to severe plaque psoriasis (STA)

Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs (MTA)

Daclatasvir for treating chronic hepatitis C (STA)

Dinutuximab for high-risk neuroblastoma (STA)

Exploring the assessment and appraisal of regenerative medicines and cell therapy products (Methods project)

High-throughput, non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation (DAR)

Review of ERG exploratory analysis (Project led by ScHARR-TAG) (Methods project)

Ruxolitinib for the treatment of myelofibrosis (STA)

Vortioxetine for treating major depressive disorder (STA)

2014

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis (Review of TA143) (MTA)

Best practice pathways and outcome measures for mental health crisis care (HTA TAR)

Graduated compression stockings for prevention of deep vein thrombosis in postoperative surgical patients (HTA TAR)

Lubiprostone for treating chronic idiopathic constipation (STA)

Lubiprostone for treating opioid-induced constipation in people with chronic, non-cancer pain (STA)

Ustekinumab for psoriatic arthritis (STA Rapid review)

2013

Aflibercept in combination with irinotecan and fluorouracil-based therapy for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy (STA)

Crizotinib for the treatment of non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene (STA)

Dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis (STA)

Interventions for adult Eustachian tube dysfunction: a systematic review (HTA Short Report)

Ipilimumab for previously untreated unresectable malignant melanoma (STA)

The use of measures of obesity in childhood for predicting obesity and the development of obesity-related diseases in adulthood (HTA TAR)

Teriflunomide for the treatment of relapsing forms of multiple sclerosis (STA)

Ustekinumab for the treatment of active and progressive psoriatic arthritis (STA)

2012

Adjunctive colposcopy technologies for examination of the uterine cervix (DAR)

Bone turnover markers for monitoring the response to osteoporosis treatment (HTA TAR)

Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation (MTA)

Ruxolitinib for the treatment of myelofibrosis (STA)

2011

EOS low dose 2D/3D X-ray imaging system (DAR)

Fingolimod for relapsing or remitting multiple sclerosis (STA)

Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation (STA)

The clinical and cost-effectiveness of low-intensity psychological interventions for the secondary prevention of relapse after depression (HTA Short Report)

The clinical and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery (HTA TAR)

2010

Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer (STA)

Capecitabine for the treatment of advanced gastric cancer (STA)

Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (STA)

Golimumab for the treatment of psoriatic arthritis (STA)

Growth monitoring for short stature (HTA Short Report)

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 (STA)

Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (STA)

2009

Aldosterone antagonists for post-MI heart failure (HTA TAR)

Alitretinoin for the treatment of severe chronic hand eczema (STA)

Dronedarone within its licensed indication for the treatment of atrial fibrillation and atrial flutter (STA)

Paracetamol and selective and NSAIDs for the reduction of morphine-related side-effects after major surgery (HTA TAR)

Systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin (HTA TAR)

The clinical and cost effectiveness of etanercept, infliximab and adalimumab - psoriatic arthritis (MTA)

Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix (STA)

2008

Adverse effects in economic models: are they incorporated adequately and appropriately? (HTA Short Report - Methods)

Antiviral drugs for the treatment of influenza (MTA)

Enhanced EECP for the treatment of stable angina and heart failure (HTA Short Report)

Endovascular stents for abdominal aortic aneurysms (MTA)

Sugammadex for reversal of muscle relaxation in general anaesthesia (HTA TAR)

Systematic review of presumed consent systems for cadaveric organ donation (HTA Short Report)

2007

Clinical and cost effectiveness of rimonabant within its licensed indications as an adjunct to diet and exercise for the treatment of obese and overweight patients (STA)

Continuous positive airways pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (MTA)

Curative catheter ablation in atrial fibrillation and typical atrial flutter (HTA TAR)

Stapled haemorrhoidectomy (haemorrhoidopexy) for the treatment of haemorrhoids (MTA)

The effect of withdrawal of clopidogrel in patients with ischaemic heart disease (HTA Short Report)

2006

Systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery (HTA TAR)

Systematic review and economic model of the clinical effectiveness and cost effectiveness of interventions for preventing relapse in people with bipolar disorder (HTA TAR)

2005

Etanercept and efalizumab for the treatment of psoriasis (MTA)

Etanercept and infliximab for the treatment of psoriatic arthritis (MTA)

Systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer (MTA)

2004

Review of guidelines for good practice in decision-analytic modelling in health technology assessment (HTA Short Report)

Systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents (MTA)

Systematic review of effectiveness of different treatments for childhood retinoblastoma (MTA)

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (MTA)

2003

A rapid and systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder (MTA)

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events (MTA)

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults (MTA)

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes (MTA)

Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine for locally advanced and/or metastatic breast cancer (MTA)

2002

Effectiveness and cost-effectiveness of acute hospital-based spinal cord injuries services (MTA)

Systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists (MTA)

Taxanes for ovarian cancer: update (MTA)

The clinical and cost-effectiveness of vinorelbine combination therapy for breast cancer (MTA)

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (MTA)

2001

An update of a rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast cancer (MTA)

Systematic review of atypical antipsychotic drugs in schizophrenia (MTA)

Systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the treatment of unstable angina (MTA)

Systematic review of the clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity (MTA)

The clinical and cost-effectiveness of topotecan for ovarian cancer (MTA)

The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation (MTA)

The clinical effectiveness and cost-effectiveness of pegylated liposomal doxorubicin hydrochloride for ovarian cancer (MTA)

The clinical effectiveness of trastuzumab for breast cancer (MTA)

2000

Systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity (MTA)

Systematic review of the effectiveness and cost-effectiveness of debriding agents in treating surgical wounds healing by secondary intention (MTA)

The effectiveness and cost-effectiveness of taxanes in ovarian and breast cancer (MTA)

1999

Effectiveness and cost-effectiveness of the prophylactic removal of wisdom teeth (MTA)